The burden of prostate cancer is associated with human development index: evidence from 87 countries, 1990–2016
Author:
Publisher
Springer Science and Business Media LLC
Subject
Biochemistry, medical,Health Policy,Drug Discovery
Link
http://link.springer.com/content/pdf/10.1007/s13167-019-00169-y.pdf
Reference40 articles.
1. Global Burden of Disease Cancer Collaborators. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016 a systematic analysis for the Global Burden of Disease Study. JAMA Oncol. 2018;4:1553. https://doi.org/10.1001/jamaoncol.2018.2706 .
2. Dorr M, Holzel D, Schubert-Fritschle G, Engel J, Schlesinger-Raab A. Changes in prognostic and therapeutic parameters in prostate cancer from an epidemiological view over 20 years. Oncol Res Treat. 2015;38:8–14.
3. Winter A, Sirri E, Jansen L, Wawroschek F, Kieschke J, Castro FA, et al. Comparison of prostate cancer survival in Germany and the USA: can differences be attributed to differences in stage distributions? BJU Int. 2017;119:550–9.
4. Mohler JL, Bahnson RR, Boston B, Busby JE, D'Amico A, Eastham JA, et al. Prostate cancer: clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2010;8:162–200.
5. Quinn M, Babb P. Patterns and trends in prostate cancer incidence, survival, prevalence and mortality. Part II: individual countries. BJU Int. 2002 Jul 1;90(2):174–84.
Cited by 28 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. XRCC1 and XPD polymorphisms: clinical outcomes and risk of prostate cancer in Bangladeshi population;Molecular Biology Reports;2024-08-08
2. XRCC1 and XPD Polymorphisms: Clinical Outcomes and Risk of Prostate Cancer in Bangladeshi Population;2024-04-17
3. Prostate cancer burden in major BRICS countries, 1990–2019: findings from the 2019 global burden of disease study;European Journal of Cancer Prevention;2024-04-09
4. Low-dose-rate brachytherapy as a primary treatment for localised and locally advanced prostate cancer: a systematic review of economic evaluations;Prostate Cancer and Prostatic Diseases;2024-03-13
5. Lutetium-177 Labelled Anti-PSMA Monoclonal Antibody (Lu-TLX591) Therapy for Metastatic Prostate Cancer: Treatment Toxicity and Outcomes;Molecular Diagnosis & Therapy;2024-03-06
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3